Tissue and soluble biomarkers in breast cancer and their applications: Ready to use?

Marco Danova, Sara Delfanti, Mariangela Manzoni, Sara Mariucci

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Breast cancer therapies are in continuous evolution: From surgery to hormonal therapy, from classical and new combined chemotherapies to emerging targeted agents of recent introduction to the clinic. The attempt to personalize the best treatment for each patient is driven by efficacy and safety parameters and tumor biology investigations of markers for aggressiveness and response to treatment. The plethora of targeted therapies has provided momentum for the quest to better understand not only target mechanisms of action, but also tumor behavior. Moreover, how to monitor response to these agents is crucial today to achieve better resource-sharing and to find cheaper, less invasive, and standardized detection techniques for clinically validated biomarkers. In this report, we briefly summarize data on the major tissue and soluble biomarkers focusing on their actual use in daily practice, as well as their emerging role and possible future applications in breast cancer treatment.

Original languageEnglish
Pages (from-to)75-78
Number of pages4
JournalJournal of the National Cancer Institute - Monographs
Issue number43
DOIs
Publication statusPublished - Oct 2011

Fingerprint

Biomarkers
Breast Neoplasms
Therapeutics
Neoplasms
Safety
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Tissue and soluble biomarkers in breast cancer and their applications : Ready to use? / Danova, Marco; Delfanti, Sara; Manzoni, Mariangela; Mariucci, Sara.

In: Journal of the National Cancer Institute - Monographs, No. 43, 10.2011, p. 75-78.

Research output: Contribution to journalArticle

@article{f5cbb279516e42ed8e7ef6d627294319,
title = "Tissue and soluble biomarkers in breast cancer and their applications: Ready to use?",
abstract = "Breast cancer therapies are in continuous evolution: From surgery to hormonal therapy, from classical and new combined chemotherapies to emerging targeted agents of recent introduction to the clinic. The attempt to personalize the best treatment for each patient is driven by efficacy and safety parameters and tumor biology investigations of markers for aggressiveness and response to treatment. The plethora of targeted therapies has provided momentum for the quest to better understand not only target mechanisms of action, but also tumor behavior. Moreover, how to monitor response to these agents is crucial today to achieve better resource-sharing and to find cheaper, less invasive, and standardized detection techniques for clinically validated biomarkers. In this report, we briefly summarize data on the major tissue and soluble biomarkers focusing on their actual use in daily practice, as well as their emerging role and possible future applications in breast cancer treatment.",
author = "Marco Danova and Sara Delfanti and Mariangela Manzoni and Sara Mariucci",
year = "2011",
month = "10",
doi = "10.1093/jncimonographs/lgr023",
language = "English",
pages = "75--78",
journal = "Journal of the National Cancer Institute. Monographs",
issn = "1052-6773",
publisher = "Oxford University Press",
number = "43",

}

TY - JOUR

T1 - Tissue and soluble biomarkers in breast cancer and their applications

T2 - Ready to use?

AU - Danova, Marco

AU - Delfanti, Sara

AU - Manzoni, Mariangela

AU - Mariucci, Sara

PY - 2011/10

Y1 - 2011/10

N2 - Breast cancer therapies are in continuous evolution: From surgery to hormonal therapy, from classical and new combined chemotherapies to emerging targeted agents of recent introduction to the clinic. The attempt to personalize the best treatment for each patient is driven by efficacy and safety parameters and tumor biology investigations of markers for aggressiveness and response to treatment. The plethora of targeted therapies has provided momentum for the quest to better understand not only target mechanisms of action, but also tumor behavior. Moreover, how to monitor response to these agents is crucial today to achieve better resource-sharing and to find cheaper, less invasive, and standardized detection techniques for clinically validated biomarkers. In this report, we briefly summarize data on the major tissue and soluble biomarkers focusing on their actual use in daily practice, as well as their emerging role and possible future applications in breast cancer treatment.

AB - Breast cancer therapies are in continuous evolution: From surgery to hormonal therapy, from classical and new combined chemotherapies to emerging targeted agents of recent introduction to the clinic. The attempt to personalize the best treatment for each patient is driven by efficacy and safety parameters and tumor biology investigations of markers for aggressiveness and response to treatment. The plethora of targeted therapies has provided momentum for the quest to better understand not only target mechanisms of action, but also tumor behavior. Moreover, how to monitor response to these agents is crucial today to achieve better resource-sharing and to find cheaper, less invasive, and standardized detection techniques for clinically validated biomarkers. In this report, we briefly summarize data on the major tissue and soluble biomarkers focusing on their actual use in daily practice, as well as their emerging role and possible future applications in breast cancer treatment.

UR - http://www.scopus.com/inward/record.url?scp=84855183439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855183439&partnerID=8YFLogxK

U2 - 10.1093/jncimonographs/lgr023

DO - 10.1093/jncimonographs/lgr023

M3 - Article

C2 - 22043046

AN - SCOPUS:84855183439

SP - 75

EP - 78

JO - Journal of the National Cancer Institute. Monographs

JF - Journal of the National Cancer Institute. Monographs

SN - 1052-6773

IS - 43

ER -